MiR-144-3p Promotes the Tumor Growth and Metastasis of Papillary Thyroid Carcinoma by Targeting Paired Box Gene 8

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2018 Apr 11

PMID 29632436

Citations 31

Authors

Chang Liu

Chang Su

Yanchun Chen

Guang Li

Affiliations

Soon will be listed here.

Abstract

Background: Paired box gene 8 (PAX8) is expressed in and indispensable to thyroid development. MiR-144-3p is found dys-regulated in cancers, and it can block the expression of target gens. This study sought to understand the effect of MiR-144-3p in papillary thyroid carcinoma (PTC) as well as the associated mechanisms.

Materials And Methods: Real-time PCR, immunohistochemical and Western blot assays were performed to examine the expression of target miRNA and/or genes. CCK-8 and flow cytometry analysis was used to respectively test cell growth, cell cycle progression and apoptosis. Luciferase reporter assay was performed to find out whether miR-144-3p could bind to the 3' untranslated region of PAX8 or not.

Results: We found that PAX8 decreased in PTC, while miR-144-3p increased in PTC. Over-expression of miR-144-3p promoted the cell viability and cell cycle progression. The expressions of cell-cycle-related genes, cyclin D1, cyclin-dependent kinase 2 and CDC25A were modulated by miR-144-3p. Meanwhile, the presence or absence of miR-144-3p both affected epithelial-mesenchymal transition of PTC by regulating the expression of E-cadherin, N-cadherin and vimentin. Moreover, PAX8 may be a potential direct target of miR-144-3p. Mechanically, the activation of extracellular signal-regulated kinases 1/2, Akt and c-Jun N-terminal kinases may be associated with the tumor-promoting effect of miR-144-3p. In addition, the blockage of miR-144-3p forced the anti-tumor effect delivered by X-ray exposure or paclitaxel.

Conclusion: MiR-144-3p promoted the growth of tumor and the metastasis of PTC by targeting PAX 8. The study provided promising prognosis markers and valuable treatment strategy for PTC.

Citing Articles

A Critical Review on microRNAs as Prognostic Biomarkers in Laryngeal Carcinoma.

Komitova K, Dimitrov L, Stancheva G, Kyurkchiyan S, Petkova V, Dimitrov S Int J Mol Sci. 2025; 25(24.

PMID: 39769234 PMC: 11676902. DOI: 10.3390/ijms252413468.

Highly expressed miR-144-3p promotes the proliferation, migration and invasion of colon carcinoma cells by activating the Wnt/β-catenin signaling pathway through targeting SFRP1.

Lai C, He N, Zeng J, Long C, Shi M, Li J J Cancer. 2023; 14(16):3117-3129.

PMID: 37859826 PMC: 10583587. DOI: 10.7150/jca.87792.

Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma.

Cai W, Shu L, Liu D, Zhou L, Wang M, Deng H Front Oncol. 2023; 13:1145082.

PMID: 37427143 PMC: 10324616. DOI: 10.3389/fonc.2023.1145082.

LncTUG1 contributes to the progression of hepatocellular carcinoma via the miR-144-3p/RRAGD axis and mTOR/S6K pathway.

Chen W, Bai Z, Bai W, Wang W, Guo J, Guo M Sci Rep. 2023; 13(1):7500.

PMID: 37160972 PMC: 10170139. DOI: 10.1038/s41598-023-33976-5.

MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions.

Macerola E, Poma A, Vignali P, Proietti A, Torregrossa L, Ugolini C J Endocrinol Invest. 2023; 46(8):1651-1662.

PMID: 36749451 PMC: 10349002. DOI: 10.1007/s40618-023-02023-5.

References

Lou N, Ruan A, Qiu B, Bao L, Xu Y, Zhao Y . miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 2016; 35(1):36.e7-36.e14. DOI: 10.1016/j.urolonc.2016.07.012. View

Guo H, Ingolia N, Weissman J, Bartel D . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-40. PMC: 2990499. DOI: 10.1038/nature09267. View

Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. DOI: 10.1210/er.2007-0007. View

Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M . PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol. 2004; 151(3):367-74. DOI: 10.1530/eje.0.1510367. View

Uzgare A, Kaplan P, Greenberg N . Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate. 2003; 55(2):128-39. DOI: 10.1002/pros.10212. View

Sharma R, Sanchez-Ferras O, Bouchard M . Pax genes in renal development, disease and regeneration. Semin Cell Dev Biol. 2015; 44:97-106. DOI: 10.1016/j.semcdb.2015.09.016. View

Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R . Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2007; 21(2):192-200. DOI: 10.1038/modpathol.3801002. View

Caron R, Yacoub A, Mitchell C, Zhu X, Hong Y, Sasazuki T . Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells. Cell Cycle. 2005; 4(3):456-64. DOI: 10.4161/cc.4.3.1249. View

Nga M, Lim G, Soh C, Kumarasinghe M . HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol. 2008; 36(8):550-6. DOI: 10.1002/dc.20841. View

10.

Diao W, Luo L, Luo Q . Effect of X-ray irradiation on epithelial-mesenchymal transition of colorectal cancer SW480 cells. J Biol Regul Homeost Agents. 2016; 30(2):553-58. View

11.

Wang J, Levin P . Metabolism, cell growth and the bacterial cell cycle. Nat Rev Microbiol. 2009; 7(11):822-7. PMC: 2887316. DOI: 10.1038/nrmicro2202. View

12.

Tanzer A, Stadler P . Molecular evolution of a microRNA cluster. J Mol Biol. 2004; 339(2):327-35. DOI: 10.1016/j.jmb.2004.03.065. View

13.

Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami C, Di Loreto C . Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. Anticancer Res. 2000; 20(1A):311-6. View

14.

Sherman S . Thyroid carcinoma. Lancet. 2003; 361(9356):501-11. DOI: 10.1016/s0140-6736(03)12488-9. View

15.

Pan H, Wen Z, Huang Y, Cheng X, Wang G, Zhou Y . Down-regulation of microRNA-144 in air pollution-related lung cancer. Sci Rep. 2015; 5:14331. PMC: 4585805. DOI: 10.1038/srep14331. View

16.

Lan F, Yu H, Hu M, Xia T, Yue X . miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met. J Neurochem. 2015; 135(2):274-86. DOI: 10.1111/jnc.13272. View

17.

Calin G, Ferracin M, Cimmino A, Di Leva G, Shimizu M, E Wojcik S . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17):1793-801. DOI: 10.1056/NEJMoa050995. View

18.

Ros P, Rossi D, Acebron A, Santisteban P . Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie. 1999; 81(4):389-96. DOI: 10.1016/s0300-9084(99)80086-8. View

19.

Raman P, Koenig R . Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol. 2014; 10(10):616-23. PMC: 4290886. DOI: 10.1038/nrendo.2014.115. View

20.

Namlos H, Meza-Zepeda L, Baroy T, Ostensen I, Kresse S, Kuijjer M . Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 2012; 7(10):e48086. PMC: 3485010. DOI: 10.1371/journal.pone.0048086. View